Search results
Results From The WOW.Com Content Network
Human immunodeficiency virus (HIV) infection remains an ongoing problem and a key public health interest. Experts are interested in finding the best strategies for HIV prevention, including the ...
The study found that twice-yearly lenacapavir for pre-exposure prophylaxis (PrEP) was highly efficacious at reducing HIV infections, reducing them by 96% compared to background HIV incidence.
Stopping the Virus From Replicating. Scientists first identified HIV in 1983, but the virus has been with us longer. Research suggests HIV probably infected its first human about a century ago.
Lenacapavir was approved for medical treatment in the European Union in August 2022, [10] [12] in Canada in November 2022, [5] [6] and in the United States in December 2022. [9] [11] [13] [14] It is the first of a class of drugs called capsid inhibitors to be approved by the US Food and Drug Administration (FDA) for treating HIV/AIDS. [11] [15]
Rilpivirine, sold under the brand names Edurant and Rekambys, is a medication, developed by Tibotec, used for the treatment of HIV/AIDS. [5] [6] It is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) with higher potency, longer half-life and reduced side-effect profile compared with older NNRTIs such as efavirenz.
The combination is indicated for the treatment of human immunodeficiency virus 1 (HIV 1) infection in people weighing at least 14 kilograms (31 lb) without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir. [6] [7]
For premium support please call: 800-290-4726 more ways to reach us
Darunavir is an Office of AIDS Research Advisory Council (DHHS) recommended treatment option for adults and adolescents, regardless of whether they have received HIV treatment in the past. [ 14 ] [ 15 ] In a study of people that had never received HIV treatment, darunavir was as effective as lopinavir / ritonavir at 96 weeks with a once-daily ...